Clinical Trial Update: Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating belantamab mafodotin as pre- and post-autologous stem cell transplant and maintenance therapy for multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Blenrep (belantamab mafodotin)

Snippet

Sponsor: University of Pennsylvania | Conditions: Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING